These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35429661)

  • 21. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
    Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
    Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].
    Jin Y; Wang AY; Wang XB; Yang HZ; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
    Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients.
    Kernan NA; Klein E; Mauguen A; Torok-Castanza J; Prockop SE; Scaradavou A; Curran K; Spitzer B; Cancio M; Ruggiero J; Allen J; Harris A; Oved J; O'Reilly RJ; Boelens JJ
    Transplant Cell Ther; 2024 Jul; 30(7):692.e1-692.e12. PubMed ID: 38643958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
    Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML.
    Klyuchnikov E; Christopeit M; Badbaran A; Bacher U; Fritzsche-Friedland U; von Pein UM; Wolschke C; Kröger N
    Eur J Haematol; 2021 May; 106(5):606-615. PubMed ID: 33249666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic value of donor chimerism at +90 days after allogeneic hematopoietic stem cell transplantation in young patients with intermediate-risk acute myeloid leukemia].
    Fei Y; Hu XX; Chen Q; Huang AJ; Cheng H; Ni X; Qiu HY; Gao L; Tang GS; Chen J; Zhang WP; Yang JM; Wang JM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):990-995. PubMed ID: 32023728
    [No Abstract]   [Full Text] [Related]  

  • 33. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.
    Fan S; Pan TZ; Dou LP; Zhao YM; Zhang XH; Xu LP; Wang Y; Huang XJ; Mo XD
    Front Immunol; 2023; 14():1091014. PubMed ID: 36817493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
    Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
    Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
    J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
    Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia.
    Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Wolschke C; Bacher U; Kröger N
    Transplant Cell Ther; 2021 Oct; 27(10):841-850. PubMed ID: 34118468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.